Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677593 | 0.81 | SMN1; SMN2 (0.44) | EPHX2KMT2ASMN1; SMN2EPHX1KDM4E | |
| SCHEMBL3543759 | 0.78 | EPHX1 (0.47) | EPHX2KMT2AFAAHSMN1; SMN2EPHX1 | |
| SCHEMBL3546747 | 0.77 | SMN1; SMN2 (0.39) | EPHX2KMT2AMEN1SMN1; SMN2EPHX1 | |
| SCHEMBL16509284 | 0.76 | CXCR4 (0.42) | EPHX2KMT2ASMN1; SMN2EPHX1RAB9A | |
| SCHEMBL18743820 | 0.75 | KDM1A (0.47) | KMT2AMEN1FAAHMAPK1EPHX1 | |
| SCHEMBL14007446 | 0.75 | CXCR4 (0.45) | EPHX2KMT2ASMN1; SMN2EPHX1RAB9A | |
| SCHEMBL28549536 | 0.74 | ALDH1A1 (0.53) | EPHX2SMN1; SMN2EPHX1KDM4EALDH1A1 | |
| SCHEMBL20857323 | 0.73 | HPGD (0.56) | KMT2AMEN1FAAHMAPK1SMN1; SMN2 | |
| SCHEMBL13368150 | 0.73 | SMN1; SMN2 (0.53) | EPHX2KMT2AMEN1FAAHMAPK1 | |
| SCHEMBL619500 | 0.73 | EPHX2 (0.62) | EPHX2SMN1; SMN2KDM4EALDH1A1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20070185013-A1 | Use of chk1 inhibitors to control cell proliferation | ICOS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, PCNA, CHEK2 | EPHX2 2850/4885KMT2A 1546/4885MEN1 1983/4885 |
| US-20070185013-A1 | Use of chk1 inhibitors to control cell proliferation | CHEK1, CHEK2, CDC25C | EPHX2 2471/4885KMT2A 1006/4885MEN1 2199/4885 |
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | EPHX2 1438/4885KMT2A 4680/4885MEN1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.